To cite: Kostuj T, Rehart S, Matta-Hurtado R, et al. Pilot study for the registry of complications in rheumatic diseases from the German Society of Surgery (DGORh): evaluation of methods and data from the first 1000 patients. BMJ Open 2017;7:e015987. doi:10.1136/bmjopen-2017-015987

ABSTRACT

Objective Most patients suffering with rheumatic diseases who undergo surgical treatment are receiving immune-modulating therapy. To determine whether these medications affect their outcomes a national registry was established in Germany by the German Society of Surgery (DGORh). Data from the first 1000 patients were used in a pilot study to identify relevant risk factors and to determine whether such a registry is suitable for developing accurate and relevant recommendations.

Design and participants Data were collected from patients undergoing surgical treatments with their written consent. A second consent form was used, if complications occurred. During this pilot study, in order to obtain a quicker overview, risk factors were considered only in patients with complications. Only descriptive statistical analysis was employed in this pilot study due to limited number of observed complications and inhomogeneous data regarding the surgery and the medications the patients received. Analytical statistics will be performed to confirm the results in a future outcome study.

Results Complications occurred in 26 patients and were distributed equally among the different types of surgeries. Twenty one of these patients were receiving immune-modulating therapy at the time, while five were not. Infections were observed in 2.3% of patients receiving and in 5.1% not receiving immunosuppression.

Conclusions Due to the low number of cases, inhomogeneity in the diseases and the treatments received by the patients in this pilot study, it is not possible to develop standardised best-practice recommendations to optimise their care. Based on this observation we conclude that in order to be suitable to develop accurate and relevant recommendations a national registry must include the most important and relevant variables that impact the care and outcomes of these patients.

INTRODUCTION

Rheumatoid arthritis (RA) has a prevalence of approximately 1% in Western Europe and the USA, with a cumulative prevalence for all types of rheumatic diseases being 2%, and the incidence of inflammatory arthritis diseases in Germany is 3% (about 2.5 billion patients). About 25 years ago, approximately 25% of these patients underwent total joint replacement, yet recently, the number of these procedures as well as the number of surgical treatments in general in patients with RA has decreased in Europe, the USA and Japan. This trend could be the result of the recently introduced, very early ‘treat-to-target’ treatment and/or the use of modern anti-inflammatory medications, which have increased during the same time period. Actually, about 70% of the patients with RA have received so-called disease-modifying antirheumatic drugs (DMARDs), while about 20% are treated with biologicals such as immune-modulating therapy. This means that most of these patients, undergoing surgical treatments, are receiving immune-modulating therapy for their inflammatory arthritic diseases. However, it remains unclear whether immune-modulating medications affect the outcomes of these surgical treatments or if they contribute to an increase in the number of wound complications.
Interestingly, for most of the 20 routinely administered DMARDs or biologicals, there are surprisingly few evidence-based recommendations for their perioperative use when complications occur.\textsuperscript{2,9} For example, in the case of methotrexate, the recommendation to continue administration was based on the expert opinion of a broad international panel of rheumatologists.\textsuperscript{11} National medical societies in France, the Netherlands, the US, UK and Japan recommend that—concerning tumour-necrosis-factor alpha (TMF-\(\alpha\))—therapy should be substituted until wounds are healed.\textsuperscript{12–15} Based on this confusion, the German Society for Orthopaedics in Rheumatic Diseases (DGORh) established a national registry that included surgical patients suffering with inflammatory arthritis disease. The aim of this pilot study was to determine if data from this national registry could be used to identify risk factors to develop accurate and relevant treatment recommendations, for example, in patients with RA receiving medications who have subcutaneous or deep wound infections.

This report presents the methods used in this pilot study and the preliminary results, from the first 1000 patients.

**MATERIALS AND METHODS**

**Risk adjustment**

Based on rheumatology textbooks, published studies\textsuperscript{2,15–19} and the clinical experience of study group members, the following risk factors were identified as being possible confounders as it relates to wound disorders or non-unions in arthrodesis: diabetes mellitus, atherosclerosis, malignant tumours, cachexia due to HIV or other consuming diseases, corticoid therapy with more than 5 mg prednisolone equivalent and/or administration for more than 1 year, current or history of bacterial infection in the wound or alio loco. In addition, other risk factors that were included were: sex, age, body mass index (BMI), American Society of Anesthesiologists (ASA) Physical Status classification, alcohol and smoking history.

In order to obtain a quicker overview of these possible risk factors/possible confounders, these were only considered in those patients who had wound disorders during the pilot study. While this might have caused a bias in statistical analyses and interpretation of data concerning wound disorders, seroma and infection, we accept this, since the main focus of this pilot study was to see if risk factors are present and since we did not expect to have enough data to perform statistical analyses. In the actual registry data, this bias would not occur since all risk factors and confounders must be reported in the basic form, in order to obtain valid statistical data.

**Number and structure of centres involved in the pilot study**

A total number of 12 centres were included in the pilot study (box).

Each centre had an orthopaedic surgeon with experience treating patients with inflammatory arthritic diseases. In order to have a representative cross-section of the different types of providers in Germany, different types of departments that treat patients with rheumatic diseases were asked to participate: hospitals specialised in rheumatology, university-based hospitals, departments whose focus was elective orthopaedic surgery and departments that focus on treating patients with trauma.

**Ethical approval**

Approval to conduct the study was obtained from the ethics committee at Ruhr University in Bochum (no: 4138–11). The study was carried out in accordance with the Declaration of Helsinki. All patients included in the study were invited and gave their written informed consent in an initial consent form. This form, administered by the attending physician, included information about different types of rheumatic diseases, their onset, types of medications administered to patients with rheumatic disease, details about medication regimens (continued or interrupted, estimated time for restarting medication, etc) and surgical treatments (date and type of surgery).

If a complication occurred, a second consent form was used that included information about risk factors, date and type of observed complication, as well as indicated treatments. This pilot study focused on the following complications and treatments: wound disorders and skin necrosis (delayed removal of stitches, type of local treatment, local suture), seroma (evacuation, local suture, reoperation), subcutaneous infections (CDC A1) (with i.v. antibiotics treatment or reoperation), deep infections (CDC A2+A3) (i.v. antibiotics and reoperation). Minor complications that did not result in an appointment at the outpatient department or readmission but instead were treated in a doctor’s office were not taken into account.

**Patients**

Every patient suffering from inflammatory arthritis disease and receiving surgical treatment in one of the

---

**Box Departments participating in the pilot study**

- Orthopedic Hospital Harthausen, Bad Aibling
- Department of Rheuma-Surgery, Kreuznacher Diakonie, Bad Kreuznach
- Department of Rheuma-Surgery, Red Cross Hospital, Bremen
- Department of Rheuma-Orthopaedics, St. Elisabeth Hospital, University Hospital (Ruhr University Bochum), Bochum
- Orthopaedics, Traumatology and Rheuma-Orthopaedics Clinic, Catholic Hospital Dortmund-West, Dortmund
- Orthopaedics and Traumatology Clinic, Agaplesion Markus Hospital, Frankfurt/Main
- Orthopaedics, Traumatology and Rheuma-Orthopaedics Clinic, Westpfalzclinc Kusel, Kusel
- Orthopaedic and Polyclinic, University Hospital Leipzig, Leipzig
- Rheuma-orthopedics, Rheinisches Centre for Rheumatology Meerbusch, Meerbusch
- Orthopaedic Department, Collm-Clinic Oschatz, Oschatz
- Rheuma-Orthopaedics, North-Western Centre for Rheumatology St Josef-Stift Sendenhorst, Sendenhorst
centres was asked to participate in this study and was included after written informed consent was given. Inflammatory arthritis and elective surgical treatment in the musculoskeletal system was the only inclusion criteria. No exclusion criteria were defined. No dropouts/withdrawal of consent occurred during this pilot study. The majority of the patients included in this pilot study (871 cases, 87%) suffered from RA, while 7.5% had a psoriatic arthritis, 2.8% suffered from a collagenosis and 1.8% suffered from ankylosing spondylitis. Other rare diagnoses included not differentiated inflammatory arthritis (four cases, 0.4%), Still’s disease (three cases, 0.3%) and Crohn’s disease (one case, 0.1%) (figure 1).

The median period of time from onset of the disease to the procedure leading to their inclusion in the study was 16 years, with an IQR of 10–25 years, with a maximum of 64 years and a minimum of 1 year.

Statistical methods
This article focuses on the methods and the adaptation of the questionnaires for use in the registry and reports on the initial results from the first 1000 subjects included in the database.

Due to the limited number of observed complications and the inhomogeneous type of the surgical treatments and the medications used, only descriptive statistical analysis was appropriate in this pilot study. However, analytical statistics of the confirmatory questions in midterm outcome can be expected from the registry, which was established in the summer of 2014.

Medians, interquartile ranges, CIs and significance (at 5% level) for the incidence of wound complications in patients treated with immune-modulating medication compared with those not treated were computed using SPSS V.22.0 for Windows (IBM).

RESULTS
Anti-inflammatory drugs
More than 90% of patients (902) received pharmacological therapy, with 6% (60 patients) treated with corticosteroids as a monotherapy and 20% (197 patients) receiving a combination of DMARDs or biologicals and steroids. The majority (84%, 840 patients) were treated with immune-modulating therapy based on DMARDs or biologicals, with 45% (453 patients) receiving methotrexate, either as a monotherapy (19%, 191 patients) or in combination with corticosteroids (11%, 109 patients) or adalimumab (11%, 106 patients). Other common drugs were leflunomide in (18%, 179 patients) of which 7% (67 patients) received a monotherapy, and etanercept (12%, 121 patients) of which 5% (47 patients) received a monotherapy.

Overall, more than half of all patients received a monotherapy (51%, 507 patients), while 32% were treated with two different types of medication. Combinations of three (68 patients) or four different types of immune-modulating medications (2 patients) were rare and were reported in 7% and 0.2% of patients, respectively. The reported combinations are shown in table 1.

Types of surgery
Nearly one third of all procedures can be categorised as bone and joint procedures: total joint replacements,
arthrodeses and resection arthroplasty. Different types of synovectomies were performed in 18% of patients. Surgeries in the lower extremity were represented far more often (67%, 674 cases) than those in the upper extremities (26%, 262 cases). Only two patients with surgical treatment of the vertebral column were included (0.2%). The different types of surgical treatments are listed in table 2.

### Table 1 Pharmacological therapy: steroids, disease-modifying antirheumatic drugs, biologicals and their combinations as reported

|                  | Aldalimumab | Ertanecept | Tocilizumab | Rituximab | Infliximab | Abatecept | Golimumab | MTX | Leflunomide | Azathioprine | Sulfasalazine | Hydroxychloroquine | Others | Corticoids | Total |
|------------------|-------------|------------|-------------|-----------|------------|-----------|-----------|-----|-------------|--------------|----------------|---------------------|--------|------------|-------|
| Aldalimumab      | 28          | 0          | 0           | 0         | 0          | 0         | 106       | 6   | 1           | 2            | 1              | 4                   | 0      | 68         |
| Ertanecept       | 0           | 47         | 0           | 0         | 0          | 0         | 41        | 17  | 1           | 4            | 3              | 1                   | 24     | 121        |
| Tocilizumab      | 0           | 0          | 12          | 0         | 0          | 0         | 4         | 1   | 0           | 2            | 0              | 0                   | 3      | 20         |
| Rituximab        | 0           | 0          | 0           | 16        | 0           | 0         | 11        | 2   | 0           | 2            | 2              | 0                   | 6      | 35         |
| Infliximab       | 0           | 0          | 0           | 0         | 3          | 0         | 5         | 0   | 0           | 1            | 0              | 0                   | 2      | 9          |
| Abatecept        | 0           | 0          | 0           | 0         | 0           | 3         | 6         | 2   | 0           | 0            | 1              | 0                   | 2      | 9          |
| Golimumab        | 0           | 0          | 0           | 0         | 0           | 0         | 3         | 7   | 0           | 0            | 0              | 0                   | 6      | 15         |
| MTX              | 106         | 41         | 4           | 11        | 5           | 6         | 191       | 43  | 2           | 31           | 24             | 10                  | 109    | 453        |
| Leflunomide      | 6           | 17         | 1           | 2         | 0           | 2         | 43        | 67  | 1           | 15           | 5              | 5                   | 40     | 179        |
| Azathioprine     | 1           | 1          | 0           | 0         | 0           | 0         | 2         | 1   | 10          | 0            | 1              | 0                   | 5      | 18         |
| Sulfasalazine    | 2           | 4          | 2           | 2         | 1           | 0         | 31        | 15  | 0           | 34           | 8              | 0                   | 19     | 99         |
| Hydroxychloroquine| 1         | 3          | 0           | 2         | 0           | 1         | 24        | 5   | 1           | 8            | 11             | 1                   | 22     | 57         |
| Others           | 4           | 1          | 0           | 0         | 0           | 10        | 0         | 1   | 10          | 1            | 0              | 1                   | 32     | 12         |
| Corticoids       | 6           | 24         | 3           | 6         | 2           | 2         | 6         | 109 | 40          | 5            | 19             | 22                  | 1      | 60         |

MTX, methotrexate.

### Table 2 Type of surgery performed and affected areas in the 1000 patients

|                | Tenosynovectomy | Synovectomy | Fusion or resection arthroplasty | Total joint replacement | Others | Total |
|----------------|-----------------|-------------|---------------------------------|-------------------------|--------|-------|
| Vertebra column| 7               | 8           | 3                               | 1                       | 2      | 6     |
| Shoulder       |                 |             |                                 |                         |        |       |
| Elbow          | 1               | 14          | 7                               | 6                       | 5      | 33    |
| Wrist          | 26              | 55          | 2                               | 2                       | 11     | 94    |
| Flexor tendons (hand) | 12 |             |                                 |                         |        |       |
| Extensor tendons (hand) | 19 |             |                                 |                         |        |       |
| MCP joints     | 5               | 9           | 17                              | 1                       | 32     |
| DIP/PIP joints (hand) | 4 | 19          |                                 |                         |        |       |
| Hip            |                 | 3           | 148                             | 151                     |
| Knee           | 1               | 56          | 4                               | 175                     | 4      | 240   |
| Ankle joint    | 4               | 4           | 21                              | 9                       | 5      | 43    |
| Subtalar joint | 2               | 1           | 27                              | 2                       | 32     |
| Toes           | 3               | 9           | 167                             | 1                       | 14     | 194   |
| Tendons foot   | 6               | 3           | 5                               | 5                       | 14     |
| Others         |                 |             |                                 |                         | 58     | 58    |
| Total          | 55              | 127         | 324                             | 380                     | 114    | 1000  |

DIP/PIP joints, distal interphalangeal/proximal interphalangeal joints; MCP joints, metacarpophalangeal joints.
### Table 3: Patients with reported postoperative complications

| Type of complications | Patients (n) | Type of surgery | Further risk factors postulated |
|-----------------------|--------------|-----------------|---------------------------------|
| Wound disorder stitches in situ >14 days | 5 | 1 total hip replacement, 1 ankle arthrodesis | 2 corticosteroids >1 year, 2 further risk factors as postulated |
| Wound disorder stitches in situ >14 days | 6 | 2 bursaectomy or synovectomy (elbow), 2 total joint replacement (hip/knee), 2 procedures in ankle and foot | 3 corticosteroids >5 mg prednisolone equivalent, 2 immune-modulating drugs |
| Revision due to seroma | 1 | 1 bursaectomy, 1 hip replacement | 1 corticosteroids >5 mg prednisolone equivalent |
| Revision due to synovectomy or osteosynthesis | 1 | 1 knee replacement | 1 corticosteroids >5 mg prednisolone equivalent |
| Revision due to synovectomy or osteosynthesis | 7 | 1 total elbow replacement, 1 total hip replacement, 1 elbow arthroscopy, 1 synovectomy at knee | 5 patients: 3 diabetes, 2 vascular disease |
| Revision due to seroma | 1 | 1 total elbow replacement, 1 total hip replacement, 1 knee replacement | 1 carcinoma |
| Revision due to synovectomy or osteosynthesis | 5 | 4 patients: 2 diabetes, 2 vascular disease, 1 carcinoma | 1 history with infection in addressed area and infection at loco |
| Deep infection with revision | 1 | 1 knee replacement, 1 elbow arthroscopy | 1 combination |
| Deep infection with revision | 4 | 1 knee replacement, 1 elbow arthroscopy | 3 combination |
| Revision due to seroma | 1 | 1 total knee replacement | 1 monoclonal |
| Palsy peroneal nerve | 1 | 1 total knee replacement | 1 monoclonal |

Wound disorders/infections postoperatively were the most reported complications. The number of patients affected is given in each group. Median age at surgical treatment is 64.9 years (IQR 48.8–72.0; min 13.5; max 78.0). Median duration of rheumatic disease is 20 years (IQR 11.5–29.0; min 5.0; max 46.0). Wound disorders were observed more often in patients not receiving immune-modulating medications (0.9% vs 1%). One patient with a palsy of the peroneal nerve was reported, which has so be considered as a mechanical problem.
Complications occurred

Complications, summarised as ‘wound disorders,’ and infections occurred in 26 patients (2.6%) and were nearly equally distributed among upper limb, total hip or knee replacement and foot and ankle surgeries. Twenty one of these patients received pharmacological immune-modulating therapy (interrupted perioperatively in 11 cases), while five did not receive a specific medication. A total of 2.3% of patients with an immunomodulating therapy had wound complications, while 5.1% receiving no pharmacotherapy for their rheumatoid disease experienced wound complications in the form of infections.

Deep infections requiring revision surgery occurred in nine patients, eight (0.8%) of which were being treated with immune-modulating drugs and one (0.1%) who was not receiving medication.

Of the 26 patients with wound complications, 14 (54%) had been treated with corticosteroids for more than 1 year and 9 patients (35%) were receiving doses greater than a 5 mg prednisolone equivalent. Four patients (15%) had diabetes mellitus, two patients (8%) had vascular disease in the treated limb, two patients (8%) had carcinoma (none with cachexia) and one patient (4%) had a history of infection at the time of surgery. The average age of the patients with wound disorders/infections at the time of surgery was 65 (IQR 49–72, minimum 14, maximum 78) years. The duration of the inflammatory arthritic disease was 18 (IQR 10–29, minimum 5, maximum 46) years (95% CI 11 to 27 years). Details for these 26 patients with wound complications/infections are given in table 3.

**DISCUSSION**

Our initial results in this pilot study show that wound complications occurred twice as often in patients not receiving immune-modulating medication, while deep infections were nearly equally distributed in patients receiving and not receiving drug therapy. This finding seems to be clinically relevant—even if the statistical significance was not demonstrated, using the Fisher’s exact test (p=0.168) (figure 2). However, due to the surprisingly low number of complications, the inhomogeneous surgical procedures and the variance of pharmacotherapy within the pilot data, this observation must be interpreted with care and analytical statistics cannot yet be performed.

That said, these initial observations support the need to collect additional data that include risk factors, types of surgeries and pharmacotherapy in order to be able to formulate evidence-based recommendations for these patients.

This pilot study has helped to identify possible confounders such as risk factors and loss to follow-up due to missing patient identification, both important factors that must be taken into consideration as data collection moves forward.

The postulated risk factors were found in patients with wound disorders, indicating that these risk factors will have to be considered as possible confounders in order to evaluate the influence of pharmacotherapy on wound complications. Based on this observation, these risk factors have been included in the initial patient inclusion criteria forms (‘basic questionnaire’). This will make it possible to perform risk-adjusted analyses combined with age, sex, BMI, ASA classification, alcohol and smoking history, type and onset of rheumatic disease, in the actual registry (figure 3). Taking these confounders into account will help formulate more accurate and relevant preoperative recommendations related to the influence of pharmacotherapy in these patients.

The surprisingly low number of patients with postoperative wound disorders and infection compared with the considerably higher figure published in literature can be explained by the loss to follow-up of patients with minor wound complications treated with local therapy outside the hospital. These patients were not included in this study because the ID assigned to them by their respective hospitals made follow-up impossible as they received care elsewhere. To remedy this, a patient pseudonym was generated based on non-changing patient data consisting of date and location they were attended, place of birth (city and state), Christian name and maiden name. This so called ‘salt-protected hash code’ ensures that, even in the most complicated forms and between different institutions, patients can be linked to their individual data set, helping to avoid a loss to follow-up in the actual registry.
DGORh – Sammelstatistik Bogen 1

Erfassung der Basistherapie bei Rheumaeoperationen

| Nachname | Geburtsdatum | Geschlecht |
|----------|--------------|------------|
|          | m / w        |            |

| Strasse | Pat.-Nr. (Klinikname) | Land | Postleitzahl | Wohnort |
|---------|----------------------|------|--------------|---------|
|         |                      |      |              |         |

| Sozialversicherungsnr | Geburtsort | Bundes- / Geburtsland |
|-----------------------|------------|------------------------|
|                       |            |                        |

| Datum | Monat | CRP pré-OP | Prä-OP quantitativer Rheumafaktor |
|-------|-------|------------|-----------------------------------|
|       |       | mg/l       | (optional)                        |
|       |       |            |                                   |

Generell

**Rheumadiagnose**
- R.A. < PSA < andere .................................
  Bitte spezifizieren

**Größe** (cm)
- 115 < 140 < 145 < 150 < 155 < 160 < 165 < 170
- 175 < 180 < 185 < 190 < 195 < 200 < 205 < 210

**Gewicht** (kg)
- 35 < 40 < 45 < 50 < 55 < 60 < 65 < 70
- 75 < 80 < 85 < 90 < 95 < 100 < 105 < 110

**Raucher** ja / nein

**Alkohol** ja / nein

**Rheuma seit**
- 10 < 15 < 20 < 25 < 30 < 35 < 40 < 45 < 50 < 55 < 60 < 65 < 70
- 75 < 80 < 85 < 90 < 95 < 100 < 105 < 110

**Risikofaktoren**
- keine □
- PAVK □
- Wundheilungsstörung mit Infekt □
- Nachweis pathologischer Keime □
- HIV / Kachexie □
- Kortison > 1 Jahr □
- Kortison > 5 mg □
- Infekt in der Vorgesch. im OP-Bereich □
- Karzinom □
- Diabetes mellitus □
- Infektion in der Vorgesch. allo loco □

Operation

Bei Komplikationen Bogen 2 ausfüllen

**OP Datum**
- Tag (1) 2 (3) 4 (5) 6 (7) 8 (9) 10 (11) 12 (13) 14 (15) 16 (17) 18 (19) 20 (21) 22 (23) 24 (25) 26 (27) 28 (29) 30 (31)
- Monat (1) 2 (3) 4 (5) 6 (7) 8 (9) 10 (11) 12

**CRP pré-OP**
- mg/l

**Allgemeinzustand (ASA)**
- > nicht bekannt □
- + ASA2, geringe Beeinträchtigung □
- > ASA1, gesund □
- ASA3 starke Beeintr. □
- ASA4 lebensbedr. Beeintr. □
- ASA5 moribund □

**OP Art**

| HWS | Tenosynovektomie | Synovetomie | Sehnensplitter | Arthrodese | Arthroplastik | Endoprothese |
|-----|------------------|-------------|----------------|------------|--------------|--------------|
| Re  | Li               | Re          | Li             | Re         | Li           | Re           |
|     |                  |             |                |            |              |              |
|     |                  |             |                |            |              |              |

**Schulter**

**Ellbogen**

**Handgelenk**

**Strecksehnen Hand**

**Beugesehnen Hand**

**MCP**

**MTP**

**PIP**

**DIP**

**PIP**

**DIP**

**BWS / LWS**

**Hüfte**

**Knie**

**OSG**

**USG**

**Beugesehnen Fuss**

**Strecksehnen Fuss**

**Fusswurzel**

**Rück- und Mittelfuss**

**Zehengelenke**

**Andere** □

Bitte spezifizieren

| Re  | Li | Re | Li | Re | Li | Re | Li | Re | Li |
|-----|----|----|----|----|----|----|----|----|----|
|     |    |    |    |    |    |    |    |    |    |
|     |    |    |    |    |    |    |    |    |    |
|     |    |    |    |    |    |    |    |    |    |

Allgemeine Bemerkungen: .............................................................................................................

Fortsetzung Rückseite

Kostuj T, et al. BMJ Open 2017;7:e015987. doi:10.1136/bmjopen-2017-015987

Figure 3 Continued
### Figure 3 Continued

#### Basistherapeutikum

| Handelsname z.B. | KWZ Tage | eingenommen prä-op Monate | abgesetzt / ausgeschwemmt prä-op Tage | angesetzt für Tage post-op. 0-99 Tage |
|------------------|-----------|---------------------------|--------------------------------------|-------------------------------------|
| **Abatacept**    | 13        |                           |                                     |                                    |
| **Orecia**       |           |                           |                                     |                                    |
| **Adalimumab**   | 12        |                           |                                     |                                    |
| **Humira**       |           |                           |                                     |                                    |
| **Anakinra**     | 0.2       |                           |                                     |                                    |
| **Kineret**      |           |                           |                                     |                                    |
| **Anti-lama Mittel** | 45 |                                    |                                     |                                    |
| **Nivaquine**    |           |                           |                                     |                                    |
| **Azathioprin**  | 0.2       |                           |                                     |                                    |
| **Imurek**       |           |                           |                                     |                                    |
| **Cyclophosphamid** | 0.4 |                                     |                                     |                                    |
| **Endoxan**      |           |                           |                                     |                                    |
| **Cyclosporin**  | 0.3       |                           |                                     |                                    |
| **Sandimmun**    |           |                           |                                     |                                    |
| **Elanercept**   | 4         |                           |                                     |                                    |
| **Enbrel**       |           |                           |                                     |                                    |
| **Gold**         | 45        |                           |                                     |                                    |
| **Taurafox**     |           |                           |                                     |                                    |
| **Infliximab**   | 9         |                           |                                     |                                    |
| **Remicade**     |           |                           |                                     |                                    |
| **Leflunomid**   | 14/62     |                           |                                     |                                    |
| **Arava**        |           |                           |                                     |                                    |
| **Methotrexat**  | 0.3       |                           |                                     |                                    |
| **Lantarel**     |           |                           |                                     |                                    |
| **Mycophenolsäure** | 6.25 |                                     |                                     |                                    |
| **CellCept**     |           |                           |                                     |                                    |
| **Rituximab**    | 19        |                           |                                     |                                    |
| **MabThera**     |           |                           |                                     |                                    |
| **Sulfasalazin** | 17        |                           |                                     |                                    |
| **Salazopyrin**  |           |                           |                                     |                                    |
| **Andere**       |           |                           |                                     |                                    |
| (Bitte spezifizieren) |       |                           |                                     |                                    |

*Allgemeine Bemerkungen:

______________________________________________________________

Copyright MEM Inc. 2013. All rights reserved. 01.09.2013*
**DGORh - Sammelstatistik Bogen 2**
Erfassung von Komplikationen unter Basistherapie bei Rheumaooperationen

### Komplikation

**Komplikation aufgetreten am**
- Tag
- Monat
- Jahr

#### Postoperative Komplikationen
- Thrombose
- Embolie
- Wundheilungsstörung
  - mit verzögerter Entfernung des Nahtmaterials
  - mit Sekundärnaht
  - mit besonderer Wundbehandlung
- Subkutaner Serom
  - konservativ ausgeheilt
  - punktiert
  - Sekundärnaht
  - operativ revidiert (s.u.)
- Infektion subkutan
  - konservativ ausgeheilt
  - operativ revidiert (s.u.)
- Infektion tief
  - konservativ ausgeheilt
  - operativ revidiert (s.u.)
- andere

#### Keimnachweis - Wundheilungsstörung
- ja
- nein
- nicht durchgeführt

#### Keimnachweis - Subkutaner Serom
- ja
- nein
- nicht durchgeführt

#### Keimnachweis - Infektion subkutan
- ja
- nein
- nicht durchgeführt

#### Keimnachweis - Infektion tief
- ja
- nein
- nicht durchgeführt

### Operative Revision
- ja
- nein

### Nicht operative Revision
- verzögerte Entfernung des Nahtmaterials
- i.v. Antibiotikabehandlung
- orale Antibiotikabehandlung
- besondere Wundbehandlung
- (Hydrokolloidverbände etc.)

### Revision durchgeführt am
- Tag
- Monat
- Jahr

### Risikofaktoren
- keine
- Wundheilungsstörung mit
- Kortison > 1 Jahr
- Kortison > 5mg
- HIV / Kachexie
- Karzinom
- Infektion in der Vorgeschichte im OP-Bereich
- Diabetes mellitus
- Infektion in der Vorgeschichte allo loco
- PAVK
- Infekt allo loco
- anderer

### Infektion subkutan
- konservativ ausgeheilt
- operativ revidiert

**Falls OPERATIV REVIDIERT**

| Datum | 
|------------------|
| TT.MM.JJJJ |

### Allgemeine Bemerkungen:

---

**Copyright Meka, 2013 All rights reserved 01.07.2013**

---

**Figure 3** Questionnaires adapted for use in the registry based on the findings from the pilot study.
Finally, based on this pilot study, additional data will be collected documenting in more detail the type of treatment wound disorders received and the final status of the wound complication, thus being able to distinguish between minor and major wound complications in the registry.

LIMITATIONS
Due to the small number of patients with observed complications as well as the inhomogeneity in the surgical and pharmacological treatments they received, extended analytical statistics could not be performed. Accordingly, at this time, no recommendations for perioperative management of anti-inflammatory drugs could be derived from these first 1000 datasets.

In the actual registry, the analysis of data reported in high volumes, like monotherapy and single surgeries, will be considered first line, while those occurring in low volumes like multiple surgeries or combinations of medication will be designated second line and will be analysed taking the first line into consideration.

CONCLUSION
Besides age, sex, risk factors, type and duration of the rheumatic disease, the administration of immune-modulating medications may impact wound complications. Due to the inhomogeneity in the disease itself and the treatments received by patients with rheumatic diseases, it is difficult to develop standardised best-practice recommendations to optimise their care. Therefore, the creation of a large, comprehensive national registry that includes the most important and relevant variables that impact the care and outcomes of these patients is essential. This pilot study has helped to identify these variables and in doing so will contribute to improving the national registry so that its data can be used to formulate accurate and relevant recommendations for the care of this vulnerable patient population.

Author affiliations
1Department of Orthopedics and Traumatology, Catholic Hospital Bochum, St. Josef's Hospital, University Hospital of Ruhr University Bochum, Bochum, Germany
2Institute for Medical Biometry and Epidemiology, University of Witten/Herdecke, Witten, Germany
3Clinic for Orthopedics and Traumatology, Agaplesion Markus Hospital, Teaching Hospital of Johann Wolfgang Goethe University, Frankfurt am Main, Germany
4Department of Orthopedics, Rheumatic Orthopedics and Traumatology Clinic, Catholic Hospital, Dortmund, Germany
5Orthopedic and Rheumaorthopedic Clinic-Diakonie Hospital, Bad-Kreuznach, Germany
6Department of Rheumatic Orthopedics, Catholic Hospital Bochum, St. Elisabeth Hospital, University Hospital of Ruhr University Bochum, Bochum, Germany

Acknowledgements Special thanks to the native speakers Professor John Barker and Kirsten Hartmann for their assistance editing the English content in this manuscript. Results from 873 pilot study patients were presented as a poster at the GMDS (German Society for Medical Computer Science, Biometry and Epidemiology)-Congress 2014 in Göttingen/Germany.

Collaborators Dr. Med. Ingo Arnold, Red Cross Hospital, Bremen, Department of Rheumatology and Orthopedics. Dr. Med. Ludwig Bause, St. Josef's Hospital, Department of Orthopedic Rheumatology. Dr. Med. Harald Dinges, Westfälklinikum Kusel, Clinic of Orthopedics, Traumatology and Rheumatic Orthopedics. PD Dr. med. Thomas Pauly, Rheinisches Rheumazentrum, St. Elisabeth Hospital, Department of Orthopedic Surgery/Rheumatology, Meersbusch Lank. Dr. Med. Stefan Schill, Joint Center, Rosenheim GmbH and Harthausen Bad Aibling Clinic. Dr. Med. Roger Scholz, Department of Orthopedics, Collin Clinic Oschatz.

Contributors TK: writing of manuscript, data analyses, modification of questionnaires for real-time registry. SR: design of pilot questionnaires, review of questionnaires for real time registry, review of manuscript. RMH: data collection and data analysis. CB: providing of references, review of manuscript. REW: providing of references, approval ethics committee. KS: design of pilot questionnaires, data collection, review of manuscript.

Funding External funding to perform this pilot study was not made available; however, permission to establish the online registry was granted by the German Orthopaedic Society (DGÖOC).

Competing interests TK: Pharmaceutical or medical device companies may be involved in some of the included studies; however, the details are unknown to the author. SR: Has received speaker fees from the companies Abbvie/Grünenthal/MSD/implantcast/medac. CB: Has received speaker fees from the companies Link and Abbot. The remaining authors declare no conflicts of interest.

Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. Weiss RJ, Stark A, Wick MC, et al. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis 2006;65:336–41.
2. Weiss RJ, Ehlin A, Montgomery SM, et al. Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54,579 Swedish RA inpatients. Rheumatology 2008;47:491–4.
3. da Silva E, Doran MF,Crowson CS, et al. Declining use of orthopedic surgery in patients with rheumatoid arthritis? results of a long-term, population-based assessment. Arthritis Rheum 2003;49:216–20.
4. Shourt CA, Crowson CS, Gabriel SE, et al. Orthopedic surgery among patients with rheumatoid arthritis 1980–2007: a population-based study focused on surgery rates, sex, and mortality. J Rheumatol 2012;39:481–5.
5. Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis 2010;69:686–71.
6. Momohara S, Inoue E, Ikari K, et al. Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007: data from Japanese outpatients in a single institute-based large observational cohort (ORRA). Ann Rheum Dis 2010;69:312–3.
7. Krüger K, Albrecht K, Rehart S, et al. [Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologics in inflammatory rheumatic diseases]. Z Rheumatol 2014;73:77–84.
8. Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis 2010;69:686–71.
9. Gaubitz M. [Biologics 2012]. Orthopade 2012;41:526–32.
10. Welcker M, Sternad P, Krüger K. Aktuelle Empfehlungen der Deutschen Gesellschaft für Rheumatologie - Per operatives Management klassischer und neuer. *Arthritis Rheumatikwiss, Orthopädie & Rheuma* 2014;17:24–9.

11. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis* 2009;68:1086–93.

12. Heldmann F, Dybowski F, Baraliakos X, et al. Perioperativer Umgang mit Biologika bei rheumatoiden Arthritis. *Z Rheumatol* 2011;70:14–20.

13. Goh L, Jewell T, Laversuch C, et al. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. *Rheumatol Int* 2012;32:5–13.

14. Pieringer H, Danninger K, Tzaribachev N, et al. Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively? A systematic literature review. *Yonsei Med J* 2013;54:253–7.

15. Krüger K. Perioperative medikamentöse therapie rheumatischer erkrankungen—Aktuelle Empfehlung der DGRh. *Arthritis Rheum* 2014;60:158–62.

16. Ravi B, Escott B, Shah PS, et al. A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. *Arthritis Rheum* 2012;64:3839–49.

17. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. *J Rheumatol* 2007;34:689–95.

18. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? *Ann Rheum Dis* 2011;70:1914–20.

19. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2007;66:34–45.

20. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum* 2002;46:2287–93.

21. Rehart S, Petak N. Modern disease modifying drugs in rheumatoid arthritis in the perioperative period. patients with rheumatic diseases under therapy with methotrexate, leflunomide or TNF-alpha blockers in the perioperative period. *Akt Rheumatol* 2007;32:74–7.